These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 24641828)
21. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. Parrondo RD; Reljic T; Iqbal M; Ayala E; Tun HW; Kharfan-Dabaja MA; Kumar A; Murthy HS Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e694-e711. PubMed ID: 32616401 [TBL] [Abstract][Full Text] [Related]
22. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Epperla N; Ahn KW; Khanal M; Litovich C; Ahmed S; Ghosh N; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M Transplant Cell Ther; 2021 Jan; 27(1):58-66. PubMed ID: 32956819 [TBL] [Abstract][Full Text] [Related]
23. Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma. Heinzelmann F; Bethge W; Beelen DW; Stelljes M; Dreger P; Engelhard M; Finke J; Kröger N; Holler E; Bornhäuser M; Müller A; Haubitz I; Ottinger H J Cancer Res Clin Oncol; 2018 Jun; 144(6):1173-1183. PubMed ID: 29623467 [TBL] [Abstract][Full Text] [Related]
24. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Hamadani M; Awan FT; Elder P; Lin TS; Porcu P; Benson DM; Blum KA; Devine SM Leuk Lymphoma; 2008 Oct; 49(10):1893-8. PubMed ID: 18949613 [TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192 [TBL] [Abstract][Full Text] [Related]
26. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004 [TBL] [Abstract][Full Text] [Related]
30. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807 [TBL] [Abstract][Full Text] [Related]
31. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110 [TBL] [Abstract][Full Text] [Related]
32. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Lazarus HM; Zhang MJ; Carreras J; Hayes-Lattin BM; Ataergin AS; Bitran JD; Bolwell BJ; Freytes CO; Gale RP; Goldstein SC; Hale GA; Inwards DJ; Klumpp TR; Marks DI; Maziarz RT; McCarthy PL; Pavlovsky S; Rizzo JD; Shea TC; Schouten HC; Slavin S; Winter JN; van Besien K; Vose JM; Hari PN Biol Blood Marrow Transplant; 2010 Jan; 16(1):35-45. PubMed ID: 20053330 [TBL] [Abstract][Full Text] [Related]
34. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Foran JM; Apostolidis J; Papamichael D; Norton AJ; Matthews J; Amess JA; Lister TA; Rohatiner AZ Ann Oncol; 1998 Aug; 9(8):865-9. PubMed ID: 9789609 [TBL] [Abstract][Full Text] [Related]
35. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All? Hamadani M; Horowitz MM J Oncol Pract; 2017 Dec; 13(12):798-806. PubMed ID: 29232542 [TBL] [Abstract][Full Text] [Related]
36. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822 [TBL] [Abstract][Full Text] [Related]
37. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Sorror ML; Logan BR; Zhu X; Rizzo JD; Cooke KR; McCarthy PL; Ho VT; Horowitz MM; Pasquini MC Biol Blood Marrow Transplant; 2015 Aug; 21(8):1479-87. PubMed ID: 25862591 [TBL] [Abstract][Full Text] [Related]
38. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314 [TBL] [Abstract][Full Text] [Related]
39. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. McClune BL; Ahn KW; Wang HL; Antin JH; Artz AS; Cahn JY; Deol A; Freytes CO; Hamadani M; Holmberg LA; Jagasia MH; Jakubowski AA; Kharfan-Dabaja MA; Lazarus HM; Miller AM; Olsson R; Pedersen TL; Pidala J; Pulsipher MA; Rowe JM; Saber W; van Besien KW; Waller EK; Aljurf MD; Akpek G; Bacher U; Chao NJ; Chen YB; Cooper BW; Dehn J; de Lima MJ; Hsu JW; Lewis ID; Marks DI; McGuirk J; Cairo MS; Schouten HC; Szer J; Ramanathan M; Savani BN; Seftel M; Socie G; Vij R; Warlick ED; Weisdorf DJ Biol Blood Marrow Transplant; 2014 Jul; 20(7):960-8. PubMed ID: 24641829 [TBL] [Abstract][Full Text] [Related]
40. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Freytes CO; Zhang MJ; Carreras J; Burns LJ; Gale RP; Isola L; Perales MA; Seftel M; Vose JM; Miller AM; Gibson J; Gross TG; Rowlings PA; Inwards DJ; Pavlovsky S; Martino R; Marks DI; Hale GA; Smith SM; Schouten HC; Slavin S; Klumpp TR; Lazarus HM; van Besien K; Hari PN Biol Blood Marrow Transplant; 2012 Aug; 18(8):1255-64. PubMed ID: 22198543 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]